Recipients and active HHV-6 infection after SCT
| Patient no. . | SCT . | Disease . | Age . | Conditioning regimen . | GVHD prophylaxis . | HLA mismatch . | Age of donor . | Active HHV-6 infection after SCT . |
|---|---|---|---|---|---|---|---|---|
| 1 | u-CBSCT | AML | 3 y 0 mo | TEPA +l-PAM | CyA | 1 | — | + |
| 2 | u-CBSCT | ALL | 5 y 0 mo | TBI + TEPA + CY | CyA | 1 | — | + |
| 3 | u-CBSCT | CAMT in aplastic phase | 10 y 9 mo | TBI + TEPA + VP16 | MTX + CyA | 2 | — | + |
| 4 | u-CBSCT | Mixed lineage leukemia | 3 y 3 mo | TEPA + CY + BU +l-PAM | CyA | 2 | — | + |
| 5 | u-CBSCT | ALL | 5 y 3 mo | TBI + TEPA + BU | CyA | 1 | — | + |
| 6 | u-CBSCT | AML | 12 y 7 mo | TBI + CY + l-PAM + BU + VP16 | CyA | 1 | — | + |
| 7 | u-CBSCT | ALL | 8 y 5 mo | TEPA + CY + l-PAM + BU | CyA | 2 | — | + |
| 8 | u-CBSCT | AML | 0 y 9 mo | TEPA + BU | CyA | 1 | — | − |
| 9 | u-CBSCT | SCID | 0 y 7 mo | CY + BU + ATG | CyA | 2 | — | − |
| 10 | u-CBSCT | WAS | 0 y 6 mo | TEPA + CY + BU + ATG | CyA | 1 | — | − |
| 11 | r-BMT | AML | 8 y 10 mo | l-PAM + BU | MTX + tacrolimus | 0 | 39 | + |
| 12 | r-PBSCT | AML | 2 y 2 mo | TBI + TEPA + CY | CyA | 2 | 37 | + |
| 13 | r-PBSCT | AML | 3 y 1 mo | TEPA + CY + l-PAM + BU | CyA | 0 | 9 | + |
| 14 | r-BMT | Fanconi anemia | 15 y 9 mo | TBI + CY | CyA | 0 | 13 | + |
| 15 | r-BMT | CML | 5 y 2 mo | TBI + TEPA + CY | MTX + CyA | 0 | 2 | + |
| 16 | r-BMT | ALL | 16 y 6 mo | TBI + TEPA + ATG | MTX + CyA | 2 | 19 | + |
| 17 | u-BMT | ALL | 15 y 9 mo | TBI + TEPA + CY | MTX + tacrolimus | 0 | 37 | + |
| 18 | r-BMT | Aplastic anemia | 6 y 5 mo | TBI + TEPA + CY | MTX + CyA | 1 | 12 | + |
| 19 | r-BMT | AML | 10 y 1 mo | TBI + TEPA + CY | MTX + CyA | 1 | 14 | + |
| 20 | r-BMT | Mixed lineage leukemia | 7 y 5 mo | TBI + CY + CA | MTX | 0 | 9 | − |
| 21 | r-BMT | Aplastic anemia | 4 y 7 mo | CY + ATG | MTX + tacrolimus | 0 | 8 | − |
| 22 | r-BMT | Adrenoleukodystrophy | 6 y 11 m | TEPA + CY + BU + ATG | MTX + CyA | 0 | 8 | − |
| 23 | u-BMT | ALL | 0 y 11 mo | TBI + TEPA + CY | MTX + CyA | 0 | 43 | − |
| 24 | r-BMT | CML | 10 y 7 mo | Femur irradiation +l-PAM + BU | MTX + CyA | 1 | 6 | − |
| 25 | r-BMT | ALL | 5 y 0 mo | l-PAM + BU | MTX + CyA | 0 | 3 | − |
| 26 | u-PBSCT | Aplastic anemia | 10 y 5 mo | TBI + CY + ALG | MTX + Tacrolimus | 0 | 30 | − |
| 27 | r-PBSCT | ALL | 14 y 5 mo | TBI + TEPA +l-PAM | MTX + CyA | 0 | 30 | − |
| Patient no. . | SCT . | Disease . | Age . | Conditioning regimen . | GVHD prophylaxis . | HLA mismatch . | Age of donor . | Active HHV-6 infection after SCT . |
|---|---|---|---|---|---|---|---|---|
| 1 | u-CBSCT | AML | 3 y 0 mo | TEPA +l-PAM | CyA | 1 | — | + |
| 2 | u-CBSCT | ALL | 5 y 0 mo | TBI + TEPA + CY | CyA | 1 | — | + |
| 3 | u-CBSCT | CAMT in aplastic phase | 10 y 9 mo | TBI + TEPA + VP16 | MTX + CyA | 2 | — | + |
| 4 | u-CBSCT | Mixed lineage leukemia | 3 y 3 mo | TEPA + CY + BU +l-PAM | CyA | 2 | — | + |
| 5 | u-CBSCT | ALL | 5 y 3 mo | TBI + TEPA + BU | CyA | 1 | — | + |
| 6 | u-CBSCT | AML | 12 y 7 mo | TBI + CY + l-PAM + BU + VP16 | CyA | 1 | — | + |
| 7 | u-CBSCT | ALL | 8 y 5 mo | TEPA + CY + l-PAM + BU | CyA | 2 | — | + |
| 8 | u-CBSCT | AML | 0 y 9 mo | TEPA + BU | CyA | 1 | — | − |
| 9 | u-CBSCT | SCID | 0 y 7 mo | CY + BU + ATG | CyA | 2 | — | − |
| 10 | u-CBSCT | WAS | 0 y 6 mo | TEPA + CY + BU + ATG | CyA | 1 | — | − |
| 11 | r-BMT | AML | 8 y 10 mo | l-PAM + BU | MTX + tacrolimus | 0 | 39 | + |
| 12 | r-PBSCT | AML | 2 y 2 mo | TBI + TEPA + CY | CyA | 2 | 37 | + |
| 13 | r-PBSCT | AML | 3 y 1 mo | TEPA + CY + l-PAM + BU | CyA | 0 | 9 | + |
| 14 | r-BMT | Fanconi anemia | 15 y 9 mo | TBI + CY | CyA | 0 | 13 | + |
| 15 | r-BMT | CML | 5 y 2 mo | TBI + TEPA + CY | MTX + CyA | 0 | 2 | + |
| 16 | r-BMT | ALL | 16 y 6 mo | TBI + TEPA + ATG | MTX + CyA | 2 | 19 | + |
| 17 | u-BMT | ALL | 15 y 9 mo | TBI + TEPA + CY | MTX + tacrolimus | 0 | 37 | + |
| 18 | r-BMT | Aplastic anemia | 6 y 5 mo | TBI + TEPA + CY | MTX + CyA | 1 | 12 | + |
| 19 | r-BMT | AML | 10 y 1 mo | TBI + TEPA + CY | MTX + CyA | 1 | 14 | + |
| 20 | r-BMT | Mixed lineage leukemia | 7 y 5 mo | TBI + CY + CA | MTX | 0 | 9 | − |
| 21 | r-BMT | Aplastic anemia | 4 y 7 mo | CY + ATG | MTX + tacrolimus | 0 | 8 | − |
| 22 | r-BMT | Adrenoleukodystrophy | 6 y 11 m | TEPA + CY + BU + ATG | MTX + CyA | 0 | 8 | − |
| 23 | u-BMT | ALL | 0 y 11 mo | TBI + TEPA + CY | MTX + CyA | 0 | 43 | − |
| 24 | r-BMT | CML | 10 y 7 mo | Femur irradiation +l-PAM + BU | MTX + CyA | 1 | 6 | − |
| 25 | r-BMT | ALL | 5 y 0 mo | l-PAM + BU | MTX + CyA | 0 | 3 | − |
| 26 | u-PBSCT | Aplastic anemia | 10 y 5 mo | TBI + CY + ALG | MTX + Tacrolimus | 0 | 30 | − |
| 27 | r-PBSCT | ALL | 14 y 5 mo | TBI + TEPA +l-PAM | MTX + CyA | 0 | 30 | − |
u indicates unrelated; AML, acute myeloblastic leukemia; TEPA, thiotepa; l-PAM, melphalan; CyA, cyclosporin A; ALL, acute lymphoblastic leukemia; TBI, total body irradiation; CY, cyclophosphamide; CAMT, congenital amegakaryocytic thrombocytopenia; MTX, methotrexate; BU, busulfan; VP16, etoposide; SCID, severe combined immunodeficiency; ATG, antithymocyte globulin; WAS, Wiscott-Aldrich syndrome; r, related; CA, cytarabine; CML, chronic myelogenous leukemia; CML, chronic myelogenous leukemia; and ALG, antilymphocyte globulin.